Effects of perioperative hydrogen inhalation on brain edema and prognosis in patients with glioma.
Dong-Mei L, Jian-Qiang Y, Yan-E M · Frontiers in neurology · 2025
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
This narrative review examined the available evidence on molecular hydrogen. ( 1 ) conducted a pioneering randomized controlled trial (RCT) to evaluate perioperative hydrogen inhalation in glioma patients, demonstrating a statistically significant reduction in postoperative brain edema and improved short-term neurological outcomes. This commentary addresses methodological limitations, contextualizes the results within existing evidence on hydrogen therapy, and proposes directions for advancing this field. However, several statistical limitations should be considered for attention: sample size and generalizability: the single-center trial enrolled 120 participants, which is modest for evaluating clinical outcomes in heterogeneous glioma populations. The reviewed evidence supports molecular hydrogen's therapeutic potential. Additional well-designed studies are needed to clarify clinical safety and effectiveness.
What the Review Examined
The review examined effects of perioperative hydrogen inhalation on brain edema and prognosis in patients with glioma.
Main Findings Across the Literature
Mechanistic and clinical context: hydrogen's antioxidant and anti-inflammatory properties, well-documented in preclinical studies ( 5 ), provided a reasonable mechanism for reducing edema.
H₂ Mechanisms / Biological Findings
Mechanistic and clinical context: hydrogen's antioxidant and anti-inflammatory properties, well-documented in preclinical studies ( 5 ), provided a reasonable mechanism for reducing edema. Hydrogen, a novel therapeutic molecule, regulates oxidative stress, inflammation, and apoptosis.
Areas of Agreement or Uncertainty
This commentary addresses methodological limitations, contextualizes the results within existing evidence on hydrogen therapy, and proposes directions for advancing this field. However, several statistical limitations should be considered for attention: sample size and generalizability: the single-center trial enrolled 120 participants, which is modest for evaluating clinical outcomes in heterogeneous glioma populations.
Authors’ Conclusion
The authors concluded that mechanistic and clinical context: hydrogen's antioxidant and anti-inflammatory properties, well-documented in preclinical studies ( 5 ), provided a reasonable mechanism for reducing edema.
Limitations Reported by the Authors
This commentary addresses methodological limitations, contextualizes the results within existing evidence on hydrogen therapy, and proposes directions for advancing this field. However, several statistical limitations should be considered for attention: sample size and generalizability: the single-center trial enrolled 120 participants, which is modest for evaluating clinical outcomes in heterogeneous glioma populations.